LifeSci Acquisition III registered to offer 7.5 million shares at $10 each. No warrants will be included.
The SPAC will target companies in North America or Europe that are developing assets in the biopharma, medical technology, digital health, and healthcare services sectors.
LifeSci III is led by CEO and Director Andrew McDonald, who is chairman and CEO of LifeSci Acquisition II. He was chairman and CEO of LifeSci Acquisition until it closed its business combination with Vincera Pharma in December. Andrew is CEO of Attune Pharmaceuticals and is a founding partner of LifeSci Advisors and LifeSci Capital.
LifeSci Capital and Ladenburg Thalmann are joint book-running managers. The underwriters have an over-allotment option to purchase up to an additional 1.125 million shares.
The SPAc intends to apply for a listing on the Nasdaq under LSAC. Read more.
